Drug-Eluting Compared With Bare-Metal Coronary Stents Among Elderly Patients

Journal of the American College of Cardiology

Volumn 51, Issue 21, 2008, Pages 2017-2024

  Groeneveld, Peter W ^a,b,c   Matta, Mary Anne ^b   Greenhut, Alexis P ^b   Yang, Feifei ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METAL;

ACUTE HEART INFARCTION; AGED; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY STENT; DRUG ELUTING STENT; ELDERLY CARE; FEMALE; HAZARD RATIO; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MEDICARE; MYOCARDIAL INFARCTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; STENTS; TREATMENT OUTCOME; UNITED STATES;

EID: 43549103743     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.01.057     Document Type: Article

References (24)

1. U.S. Food and Drug Administration. FDA approves drug-eluting stent for clogged heart arteries (2003). http://www.fda.gov/bbs/topics/NEWS/2003/NEW00896.html Accessed April 24, 2007
2. Maisel W.H. Unanswered questions-drug-eluting stents and the risk of late thrombosis. N Engl J Med 356 (2007) 981-984
3. Kozac L.J., DeFrances C.J., and Hall M.J. National Hospital Discharge Survey: 2004 annual summary with detailed diagnosis and procedure data. National Center for Health Statistics. Vital Health Stat 13 (2006) 173-191
4. Gurel O. Drug-Eluting Stent Market: $5 Billion Turning on a Dime (2006). http://www.midwestbusiness.com/news/viewnews.asp?newsletterID=15086 Accessed April 23, 2007
5. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
6. Park S.J., Shim W.H., Ho D.S., et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 348 (2003) 1537-1545
7. Schofer J., Schluter M., Gershlick A.H., et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362 (2003) 1093-1099
8. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
9. Jensen L.O., Maeng M., Kaltoft A., et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 50 (2007) 463-470
10. Waksman R., Buch A.N., Torguson R., et al. Long-term clinical outcomes and thrombosis rates of sirolimus-eluting versus paclitaxel-eluting stents in an unselected population with coronary artery disease (REWARDS registry). Am J Cardiol 100 (2007) 45-51
11. Farb A., and Boam A.B. Stent thrombosis redux-the FDA perspective. N Engl J Med 356 (2007) 984-987
12. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127 (1997) 757-763
13. Rosenbaum P.R., and Rubin D.B. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39 (1985) 33-38
14. Lash T.L., and Silliman R.A. A comparison of the National Death Index and Social Security Administration databases to ascertain vital status. Epidemiology 12 (2001) 259-261
15. D'Agostino Jr. R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17 (1998) 2265-2281
16. DiPrete T.A., and Gangl M. Assessing bias in the estimation of causal effects. Sociol Methodol 34 (2004) 271-310
17. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
18. Holmes Jr. D.R., Leon M.B., Moses J.W., et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 (2004) 634-640
19. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
20. Stone G.W., Ellis S.G., Cox D.A., et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109 (2004) 1942-1947
21. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
22. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
23. Austin P.C. The performance of different propensity score methods for estimating marginal odds ratios. Stat Med 26 (2007) 3078-3094
24. National Institute for Health and Clinical Excellence. Ischaemic heart disease-coronary artery stents (review): appraisal consultation document (2007). http://guidance.nice.org.uk/page.aspx?o=445413 Accessed August 2, 2007